All In Biotech

Drug Trial Radar · NCT01777152

ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas

Last checked: Nov 19, 2026Latest source record: Nov 30, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 452 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

452

Actual

Start

Jan 31, 2013

Primary completion

Aug 15, 2018

Study completion Oct 2, 2020

Sponsor

Lead sponsor
Seagen Inc.Pfizer (PFE)
Sponsor type
Industry
Collaborators
Millennium Pharmaceuticals, Inc.
First posted
Jan 28, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.

Conditions

  • Anaplastic Large-Cell Lymphoma
  • Non-Hodgkin Lymphoma
  • T-Cell Lymphoma

Interventions

  • brentuximab vedotinDrug

    1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles

  • doxorubicinDrug

    50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

  • prednisoneDrug

    100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles

  • vincristineDrug

    1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles

  • cyclophosphamideDrug

    750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival Per Independent Review Facility (IRF)Time frame: Up to 60 months

Locations

144 sites in 16 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Stanford Cancer Center

    Stanford, California

  • Shands Cancer Center / University of Florida

    Gainesville, Florida

  • Orlando Health, Inc.

    Orlando, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • Cardinal Bernardin Cancer Center / Loyola University Medical Center

    Maywood, Illinois

  • Holden Comprehensive Cancer Center / University of Iowa

    Iowa City, Iowa

  • University of Kansas Cancer Center

    Westwood, Kansas

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Memorial Sloan Kettering Cancer Center - Basking Ridge

    Basking Ridge, New Jersey

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering Cancer Center - Commack

    Commack, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • Weill Cornell Medical College

    New York, New York

  • James P. Wilmot Cancer Center / University of Rochester Medical Center

    Rochester, New York

  • Albert Einstein Cancer Center

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Jewish Hospital, The

    Cincinnati, Ohio

  • Cleveland Clinic, The

    Cleveland, Ohio

  • Mercy Clinic Oncology

    Oklahoma City, Oklahoma

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • Charles A. Sammons Cancer Center / Baylor University Medical Center

    Dallas, Texas

  • MD Anderson Cancer Center / University of Texas

    Houston, Texas

  • University of Virginia

    Charlottesville, Virginia

  • Virginia Commonwealth University Medical Center

    Richmond, Virginia

  • Benaroya Research Institute/Virginia Mason Medical Center

    Seattle, Washington

  • Seattle Cancer Care Alliance / University of Washington

    Seattle, Washington

  • Royal Adelaide Hospital

    Adelaide, Australia

  • Moorabbin Hospital

    Bentleigh East, Australia

  • Icon Cancer Care Chermside

    Chermside, Australia

  • Icon Cancer Care South Brisbane

    Chermside, Australia

  • Icon Cancer Care Southport

    Chermside, Australia

  • Icon Cancer Care Wesley

    Chermside, Australia

  • Monash Medical Centre

    Clayton, Australia

  • Concord Repatriation General Hospital

    Concord, Australia

Showing 40 of 144 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.